WAAW 2022: Preventing Antimicrobial Resistance Together
The World Antimicrobial Awareness Week (WAAW) was introduced by the World Health Organization (WHO) to increase global awareness of antimicrobial resistance (AMR). WAAW takes place annually from 18 to 24 November. During this week best practices are shared with the general public, healthcare workers and policymakers to highlight the importance of stopping the further emergence and spread of antibiotic resistance. This year’s theme is “Preventing Antimicrobial Resistance Together”.
A United Front
The COMBACTE projects were created to meet the challenges of clinical development of antibacterials in response to the worldwide growing problem of antibiotic resistance. In collaboration with other consortia within the Innovative Medicines Initiative (IMI) New Drugs 4 Bad Bugs (ND4BB) program, the projects will enable more rapid and efficient development and commercialization of much-needed new antibacterial treatments and diagnostic tests.
This IMI program represents an unprecedented partnership between industry, academia and biotech organizations to combat antibiotic resistance in Europe by tackling the scientific, regulatory, and business challenges that are hampering the development of new antibiotics.
Scientific Results
The COMBACTE consortium has generated many results through the years, related to research on antimicrobials, resistant bacteria, statistical and mathematical modelling on resistance, and so on. Our Publication Library is a testament to this research, with 150 scientific papers published in journals such as the Lancet, Jama, CID, CMI, BMJ Open, Nature, JAC and so on.
A selection of publications on antimicrobial resistance can be found below.
Publications
The antimicrobial resistance travel tool, an interactive evidence-based educational tool to limit antimicrobial resistance spread
https://doi.org/10.1093/jtm/taac045
Good Epidemiological Practice: A Narrative Review of Appropriate Scientific Methods to Evaluate the Impact of Antimicrobial Stewardship Interventions
https://doi.org/10.1016/j.cmi.2017.05.019
Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study
https://doi.org/10.1016/j.ijantimicag.2021.106345
Detection and prevalence of Carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Network: A COMBACTE LAB-Net Survey
PK/PD Modelling
“Modelling of PK/PD can support dosing optimization with the objectives to maximize efficacy and minimize resistance and toxicity” says Femke. “We developed several population PK models for old antibiotics (amoxicillin, clavulanic acid and imipenem) to evaluate and improve dosing regimens. These antibiotics were developed decades ago when PK/PD principles were largely unknown and sophisticated population PK methods did not exist. So in fact, we redeveloped the dosing of these agents.”
Related updates
Webinar Combatting Antimicrobial Resistance: The Legacy of the IMI COMBACTE Projects
On May 31st, the Innovative Health Initiative will host an Impact Webinar spotlighting the significant outcomes of the COMBACTE projects in combating ...
“We Take Bigger Steps Together”
